Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
May 09 2024 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced
significant upgrades to its suite of computational tools for
comprehensive cancer analysis. These advancements to the company’s
VIA™ software solution enhance the detection and interpretation of
aneusomies, and improve the analysis, visualization,
interpretation, and reporting of data types including optical
genome mapping (OGM), next generation sequencing, and microarray,
for comprehensive assessment of hematological diseases.
Advancements to the suite of tools include:
- Enhanced Detection of Critical
Variants
- Improved sensitivity and
precision provide increased accuracy for detection of
aneusomies with variant allele fractions (VAFs) as low as 5%, with
sensitivities and positive predictive values of 95% or greater
- Increased ability to detect
small structural variants (SVs) at low allele fractions
through a reference-guided approach in a new pipeline to detect
novel SVs from OGM data
- Automated Analysis and
Interpretation of Variants
- Enhancements to automated SV
classification include critical SV data such as quality,
frequency and size to more accurately identify disease-relevant
SVs, making analysis and interpretation faster and more
efficient
- A new standardized Phred scale
calculation for SV confidence scores aligns with industry
standards and simplifies the identification of high-quality
variants, instilling confidence in users for variant calls
- New copy number variant (CNV)
dual analysis completes the variant analysis pipeline and
enables residual disease assessment with the ability to
differentiate new emergent variants from original variants
- Dynamic Visualization for
Better Representation of Findings
- Upgraded Circos plot
visualization offers a comprehensive view of the genomic
landscape, promoting clear and accurate interpretation of
datasets and differentiation between simple and complex
genomes
- Customized and automated
reporting options offer the ability to include Circos
plots, whole genome plots and ideograms for a faster and more
complete visual representation of SVs relevant to sample
analysis
“Understanding the full scope of genomic abnormalities, such as
aneuploidy, is crucial for advancing our understanding of complex
diseases, including cancer. These advancements to our VIA software
and Bionano Solve pipeline offer researchers working with OGM data
more precise and sensitive detection methods for genomic research.
We believe the upgrades announced today will improve researchers’
ability to visualize, interpret and report results in a streamlined
process that offers greater utility for the identification of
critical cancer signatures from a genome-wide perspective,”
commented Erik Holmlin, PhD, president and chief executive
officer of Bionano.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research,
and nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. Through
its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides OGM-based
testing for certain laboratory developed tests. The Company also
offers an industry-leading, platform-agnostic software solution,
which integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information,
visit www.bionano.com and www.bionanolaboratories.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "ability," “believe,” “will” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the utility of ability of the advancements to the VIA software
described in this press release to enhance the detection and
interpretation of aneusomies, and to improve the analysis,
visualization, interpretation, and reporting of data types
including OGM, next generation sequencing, and microarray, for
comprehensive assessment of hematological diseases; the ability and
utility of the advancements to the VIA software described in this
press release to provide researchers working with OGM data more
precise and sensitive detection methods for genomic research; the
ability of the upgrades announced in this press release to improve
researchers’ ability to visualize, interpret and report results in
a streamlined process that offers greater utility for the
identification of critical cancer signatures from a genome-wide
perspective ; our ability to drive adoption of the VIA software;
execution of our stated strategies and plans; and other statement
not of historical fact. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of geopolitical and macroeconomic developments, such as
recent and potential future bank failures, the ongoing conflicts
between Ukraine and Russian and Israel and Hamas, and related
sanctions, a on our business and the global economy; general market
conditions, including inflation and supply chain disruptions; the
failure of the advancements to the VIA software described in this
press release to enhance the detection and interpretation of
aneusomies, and to improve the analysis, visualization,
interpretation, and reporting of data types including OGM, next
generation sequencing, and microarray, for comprehensive assessment
of hematological diseases; the failure of the advancements to the
VIA software described in this press release to provide researchers
working with OGM data more precise and sensitive detection methods
for genomic research; the failure of the upgrades announced in this
press release to improve researchers’ ability to visualize,
interpret and report results in a streamlined process that offers
greater utility for the identification of critical cancer
signatures from a genome-wide perspective; the failure of the VIA
software to accelerate the adoption of OGM and overcome barriers to
adoption of OGM by high-volume users; the failure of our ability to
drive adoption of the VIA software; execution of our stated
strategies and plans; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts and our ability to
continue as a “going concern”; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2023
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Oct 2023 to Oct 2024